(Albany, United States) As per DelveInsight’s assessment, globally, the Non-Alcoholic Fatty Liver Disease pipeline constitutes 110+ key companies continuously working towards developing 160+ Non-Alcoholic Fatty Liver Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Non-Alcoholic Fatty Liver Disease Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Non-Alcoholic Fatty Liver Disease clinical trials studies, Non-Alcoholic Fatty Liver Disease NDA approvals (if any), and product development activities comprising the technology, Non-Alcoholic Fatty Liver Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Non-Alcoholic Fatty Liver Disease Pipeline treatment landscape of the report, click here @ Non-Alcoholic Fatty Liver Disease Pipeline Outlook

 

Key Takeaways from the Non-Alcoholic Fatty Liver Disease Pipeline Report

• DelveInsight’s Non-Alcoholic Fatty Liver Disease Pipeline analysis depicts a robust space with 110+ active players working to develop 160+ pipeline treatment therapies.
• The leading Non-Alcoholic Fatty Liver Disease Companies working in the market include BeiGene, Inventiva Pharma, Cirius Therapeutics, Inventiva Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmacetuicals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., Novartis, CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, and others
• Promising Non-Alcoholic Fatty Liver Disease Pipeline Therapies in the various stages of development include SAMe 1000 mg, LY3849891, CB4211 Dose 1, AMG 609, Resmetirom, K-877, ALT-801, and others
• On April 2023, Amgen announced a study of phase 1 clinical trials for AMG 609. This study aims to assess the safety and tolerability of AMG 609 when administered subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD).
• On April 2023, Eli Lilly and Company announced a study of phase 1 clinical trials for LY3849891. The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with nonalcoholic fatty liver disease who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype.

 

Non-Alcoholic Fatty Liver Disease Overview

Non-alcoholic fatty liver disease (NAFLD) is a broad term used to cover a spectrum of conditions that are characterized by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis), and absence of secondary causes of hepatic steatosis such as significant alcohol consumption, chronic use of medications that can cause hepatic steatosis or hereditary disorders.

 

To explore more information on the latest breakthroughs in the Non-Alcoholic Fatty Liver Disease Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight

 

Non-Alcoholic Fatty Liver Disease Emerging Drugs Profile

• Lanifibranor: Inventiva Pharma
• Belapectin: Galectin Therapeutics
• ZED 1227: Dr. Falk Pharma GmbH
• TVB-2640: Sagimet Biosciences
• ALS-L1023: AngioLab
• MN-001: MediciNova

 

Non-Alcoholic Fatty Liver Disease Pipeline Therapeutics Assessment

There are approx. 120+ key companies which are developing the therapies for Non-Alcoholic Fatty Liver Disease. The companies which have their Non-Alcoholic Fatty Liver Disease drug candidates in the most advanced stage, i.e. phase III include, Inventiva Pharma.

 

Request a sample and discover the recent advances in Non-Alcoholic Fatty Liver Disease Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight

 

Non-Alcoholic Fatty Liver Disease Drugs and Companies

• SAMe 1000 mg: Abbott
• LY3849891: Eli Lilly and Company
• AMG 609: Amgen
• Resmetirom: Madrigal Pharmaceutical Inc
• K-877: Kowa Company Ltd

 

Non-Alcoholic Fatty Liver Disease Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Non-Alcoholic Fatty Liver Disease Therapeutics Market include-

BeiGene, Inventiva Pharma, Cirius Therapeutics, Inventiva Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmacetuicals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., Novartis, CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, and others.

 

Dive deep into rich insights for drugs for Non-Alcoholic Fatty Liver Disease Pipeline, click here for Non-Alcoholic Fatty Liver Disease Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight

 

Scope of the Non-Alcoholic Fatty Liver Disease Pipeline Report

• Coverage- Global
• Non-Alcoholic Fatty Liver Disease Companies-  BeiGene, Inventiva Pharma, Cirius Therapeutics, Inventiva Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmacetuicals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., Novartis, CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, and others.
• Non-Alcoholic Fatty Liver Disease Therapies- SAMe 1000 mg, LY3849891, CB4211 Dose 1, AMG 609, Resmetirom, K-877, ALT-801, and others
• Non-Alcoholic Fatty Liver Disease Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Non-Alcoholic Fatty Liver Disease Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Non-Alcoholic Fatty Liver Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non-Alcoholic Fatty Liver Disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Lanifibranor: Inventiva Pharma
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase II/III)
11. Belapectin: Galectin Therapeutics
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. ZED 1227: Dr. Falk Pharma GmbH
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. LB-P8: LISCure Biosciences
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name : Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Non-Alcoholic Fatty Liver Disease Key Companies
24. Non-Alcoholic Fatty Liver Disease Key Products
25. Non-Alcoholic Fatty Liver Disease – Unmet Needs
26. Non-Alcoholic Fatty Liver Disease – Market Drivers and Barriers
27. Non-Alcoholic Fatty Liver Disease – Future Perspectives and Conclusion
28. Non-Alcoholic Fatty Liver Disease Analyst Views
29. Non-Alcoholic Fatty Liver Disease Key Companies
30. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services